Mirae Asset Global Investments Co. Ltd. Raises Position in Abbott Laboratories $ABT

Key Points

• Mirae Asset Global Investments increased its Abbott Laboratories stake by 38% in the second quarter, adding 522,279 shares to own 1.90 million shares valued at approximately $172 million. Institutional investors and hedge funds collectively own 75.18% of the company.
• Abbott reported quarterly earnings of $1.31 per share on $12.59 billion in revenue, exceeding analyst estimates, while revenue rose 13% year over year. The company issued 2026 EPS guidance of $5.45–$5.60.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $118.67. Abbott also pays a quarterly dividend of $0.63 per share, representing a 2.2% annualized yield.

Mirae Asset Global Investments Co. Ltd. grew its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 38.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,895,185 shares of the healthcare product maker's stock after acquiring an additional 522,279 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.11% of Abbott Laboratories worth $171,969,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of ABT. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 1.6%

ABT opened at $114.50 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The business's 50 day moving average is $99.02 and its two-hundred day moving average is $99.90. The firm has a market cap of $198.13 billion, a price-to-earnings ratio of 37.06, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. BTIG Research lifted their price target on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. JPMorgan Chase & Co. boosted their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. UBS Group lowered their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Citigroup raised their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Finally, Piper Sandler restated an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $118.67.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source